APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Prostate

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metastatic Prostate Market Analysis and Forecast 2026-2032

31 December 2025194 pages

Choose your research edition.

Industry ResearchMetastatic Prostate Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Prostate Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Metastatic Prostate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Prostate Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Prostate Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metastatic Prostate market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Metastatic Prostate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metastatic Prostate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metastatic Prostate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metastatic Prostate is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Metastatic Prostate include Genentech, BeiGene, Amgen, Zenith Epigenetics Ltd., VasGene Therapeutics, Inc., Telix Pharmaceuticals, SeleXel, Myovant Biosciences and Immunomedics(Gilead Sciences, Inc.), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Metastatic Prostate, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metastatic Prostate, also provides the revenue of main regions and countries. Of the upcoming market potential for Metastatic Prostate, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metastatic Prostate revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metastatic Prostate market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Metastatic Prostate revenue, projected growth trends, production technology, application and end-user industry.

Metastatic Prostate Segment by Company

Genentech

BeiGene

Amgen

Zenith Epigenetics Ltd.

VasGene Therapeutics, Inc.

Telix Pharmaceuticals

SeleXel

Myovant Biosciences

Immunomedics(Gilead Sciences, Inc.)

eFFECTOR Therapeutics

Arvinas Inc.

AB Science

Metastatic Prostate Segment by Type

Mono

Mono/Combination

Combination

Metastatic Prostate Segment by Application

Hospital

Drug Store

Online Pharmacy

Metastatic Prostate Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Prostate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Prostate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Prostate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Metastatic Prostate in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Metastatic Prostate company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metastatic Prostate revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metastatic Prostate Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Mono Major Player Table 3. Mono/Combination Major Player Table 4. Combination Major Player Table 5. Global Metastatic Prostate Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Drug Store Major Player Table 8. Online Pharmacy Major Player Table 9. Metastatic Prostate Industry Trends Table 10. Metastatic Prostate Industry Drivers Table 11. Metastatic Prostate Industry Opportunities and Challenges Table 12. Metastatic Prostate Industry Restraints Table 13. Global Metastatic Prostate Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Metastatic Prostate Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Metastatic Prostate Market Share by Region (2021-2026) Table 16. Global Metastatic Prostate Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Metastatic Prostate Market Share by Region (2027-2032) Table 18. Global Metastatic Prostate Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Metastatic Prostate Revenue Market Share by Players (2021-2026) Table 20. Global Metastatic Prostate Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Metastatic Prostate Key Players Headquarters & Area Served Table 22. Global Metastatic Prostate Players, Product Type & Application Table 23. Global Metastatic Prostate Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Metastatic Prostate by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Metastatic Prostate Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Metastatic Prostate Revenue Market Share by Type (2021-2026) Table 30. Global Metastatic Prostate Revenue Market Share by Type (2027-2032) Table 31. Global Metastatic Prostate Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Metastatic Prostate Revenue Market Share by Application (2021-2026) Table 35. Global Metastatic Prostate Revenue Market Share by Application (2027-2032) Table 36. Genentech Company Information Table 37. Genentech Business Overview Table 38. Genentech Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Genentech Metastatic Prostate Product Portfolio Table 40. Genentech Recent Development Table 41. BeiGene Company Information Table 42. BeiGene Business Overview Table 43. BeiGene Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. BeiGene Metastatic Prostate Product Portfolio Table 45. BeiGene Recent Development Table 46. Amgen Company Information Table 47. Amgen Business Overview Table 48. Amgen Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Amgen Metastatic Prostate Product Portfolio Table 50. Amgen Recent Development Table 51. Zenith Epigenetics Ltd. Company Information Table 52. Zenith Epigenetics Ltd. Business Overview Table 53. Zenith Epigenetics Ltd. Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio Table 55. Zenith Epigenetics Ltd. Recent Development Table 56. VasGene Therapeutics, Inc. Company Information Table 57. VasGene Therapeutics, Inc. Business Overview Table 58. VasGene Therapeutics, Inc. Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio Table 60. VasGene Therapeutics, Inc. Recent Development Table 61. Telix Pharmaceuticals Company Information Table 62. Telix Pharmaceuticals Business Overview Table 63. Telix Pharmaceuticals Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Telix Pharmaceuticals Metastatic Prostate Product Portfolio Table 65. Telix Pharmaceuticals Recent Development Table 66. SeleXel Company Information Table 67. SeleXel Business Overview Table 68. SeleXel Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. SeleXel Metastatic Prostate Product Portfolio Table 70. SeleXel Recent Development Table 71. Myovant Biosciences Company Information Table 72. Myovant Biosciences Business Overview Table 73. Myovant Biosciences Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Myovant Biosciences Metastatic Prostate Product Portfolio Table 75. Myovant Biosciences Recent Development Table 76. Immunomedics(Gilead Sciences, Inc.) Company Information Table 77. Immunomedics(Gilead Sciences, Inc.) Business Overview Table 78. Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio Table 80. Immunomedics(Gilead Sciences, Inc.) Recent Development Table 81. eFFECTOR Therapeutics Company Information Table 82. eFFECTOR Therapeutics Business Overview Table 83. eFFECTOR Therapeutics Metastatic Prostate Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. eFFECTOR Therapeutics Metastatic Prostate Product Portfolio Table 85. eFFECTOR Therapeutics Recent Development Table 86. Arvinas Inc. Company Information Table 87. Arvinas Inc. Business Overview Table 88. Arvinas Inc. Metastatic Prostate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Arvinas Inc. Metastatic Prostate Product Portfolio Table 90. Arvinas Inc. Recent Development Table 91. AB Science Company Information Table 92. AB Science Business Overview Table 93. AB Science Metastatic Prostate Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AB Science Metastatic Prostate Product Portfolio Table 95. AB Science Recent Development Table 96. North America Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Metastatic Prostate Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Metastatic Prostate Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Metastatic Prostate Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Metastatic Prostate Revenue by Country (US$ Million) & (2027-2032) Table 110. China Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 111. China Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 112. China Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 113. China Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Metastatic Prostate Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Metastatic Prostate Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Metastatic Prostate Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Metastatic Prostate Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Metastatic Prostate Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Metastatic Prostate Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Metastatic Prostate Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Metastatic Prostate Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Metastatic Prostate Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Metastatic Prostate Image Figure 2. Global Metastatic Prostate Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Prostate Market Size Share 2021 VS 2025 VS 2032 Figure 4. Mono Image Figure 5. Mono/Combination Image Figure 6. Combination Image Figure 7. Global Metastatic Prostate Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Metastatic Prostate Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drug Store Image Figure 11. Online Pharmacy Image Figure 12. Global Metastatic Prostate Market Size (US$ Million) & (2021-2032) Figure 13. Global Metastatic Prostate Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Metastatic Prostate Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Metastatic Prostate Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Metastatic Prostate Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Metastatic Prostate Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Metastatic Prostate Revenue Market Share by Type (2021-2032) Figure 20. Global Metastatic Prostate Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Metastatic Prostate Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Metastatic Prostate Revenue Market Share by Application (2021-2032) Figure 23. North America Metastatic Prostate Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Metastatic Prostate Revenue Share by Type (2021-2032) Figure 25. North America Metastatic Prostate Revenue Share by Application (2021-2032) Figure 26. North America Metastatic Prostate Revenue Share by Country (2021-2032) Figure 27. United States Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Metastatic Prostate Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Metastatic Prostate Revenue Share by Type (2021-2032) Figure 32. Europe Metastatic Prostate Revenue Share by Application (2021-2032) Figure 33. Europe Metastatic Prostate Revenue Share by Country (2021-2032) Figure 34. Germany Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Metastatic Prostate Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Metastatic Prostate Revenue Share by Type (2021-2032) Figure 44. China Metastatic Prostate Revenue Share by Application (2021-2032) Figure 45. Asia Metastatic Prostate Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Metastatic Prostate Revenue Share by Type (2021-2032) Figure 47. Asia Metastatic Prostate Revenue Share by Application (2021-2032) Figure 48. Asia Metastatic Prostate Revenue Share by Region (2021-2032) Figure 49. Japan Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Metastatic Prostate Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Metastatic Prostate Revenue Share by Type (2021-2032) Figure 57. SAMEA Metastatic Prostate Revenue Share by Application (2021-2032) Figure 58. SAMEA Metastatic Prostate Revenue Share by Country (2021-2032) Figure 59. Brazil Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Metastatic Prostate Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Mono
  • Mono/Combination
  • Combination
Applications
  • Hospital
  • Drug Store
  • Online Pharmacy
Companies covered
  • Genentech
  • BeiGene
  • Amgen
  • Zenith Epigenetics Ltd.
  • VasGene Therapeutics, Inc.
  • Telix Pharmaceuticals
  • SeleXel
  • Myovant Biosciences
  • Immunomedics(Gilead Sciences, Inc.)
  • eFFECTOR Therapeutics
  • Arvinas Inc.
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metastatic Prostate Market by Type
  3. 1.2.1 Global Metastatic Prostate Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Mono
  5. 1.2.3 Mono/Combination
  6. 1.2.4 Combination
  7. 1.3 Metastatic Prostate Market by Application
  8. 1.3.1 Global Metastatic Prostate Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drug Store
  11. 1.3.4 Online Pharmacy
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Metastatic Prostate Market Dynamics
  1. 2.1 Metastatic Prostate Industry Trends
  2. 2.2 Metastatic Prostate Industry Drivers
  3. 2.3 Metastatic Prostate Industry Opportunities and Challenges
  4. 2.4 Metastatic Prostate Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Metastatic Prostate Market Perspective (2021-2032)
  2. 3.2 Global Metastatic Prostate Growth Trends by Region
  3. 3.2.1 Global Metastatic Prostate Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metastatic Prostate Market Size by Region (2021-2026)
  5. 3.2.3 Global Metastatic Prostate Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Metastatic Prostate Revenue by Players
  2. 4.1.1 Global Metastatic Prostate Revenue by Players (2021-2026)
  3. 4.1.2 Global Metastatic Prostate Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Metastatic Prostate Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metastatic Prostate Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Metastatic Prostate Key Players Headquarters & Area Served
  7. 4.4 Global Metastatic Prostate Players, Product Type & Application
  8. 4.5 Global Metastatic Prostate Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Metastatic Prostate Market CR5 and HHI
  11. 4.6.3 2025 Metastatic Prostate Tier 1, Tier 2, and Tier 3
5 Metastatic Prostate Market Size by Type
  1. 5.1 Global Metastatic Prostate Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Metastatic Prostate Revenue by Type (2021-2032)
  3. 5.3 Global Metastatic Prostate Revenue Market Share by Type (2021-2032)
6 Metastatic Prostate Market Size by Application
  1. 6.1 Global Metastatic Prostate Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Metastatic Prostate Revenue by Application (2021-2032)
  3. 6.3 Global Metastatic Prostate Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Genentech
  2. 7.1.1 Genentech Company Information
  3. 7.1.2 Genentech Business Overview
  4. 7.1.3 Genentech Metastatic Prostate Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Genentech Metastatic Prostate Product Portfolio
  6. 7.1.5 Genentech Recent Developments
  7. 7.2 BeiGene
  8. 7.2.1 BeiGene Company Information
  9. 7.2.2 BeiGene Business Overview
  10. 7.2.3 BeiGene Metastatic Prostate Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BeiGene Metastatic Prostate Product Portfolio
  12. 7.2.5 BeiGene Recent Developments
  13. 7.3 Amgen
  14. 7.3.1 Amgen Company Information
  15. 7.3.2 Amgen Business Overview
  16. 7.3.3 Amgen Metastatic Prostate Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Metastatic Prostate Product Portfolio
  18. 7.3.5 Amgen Recent Developments
  19. 7.4 Zenith Epigenetics Ltd.
  20. 7.4.1 Zenith Epigenetics Ltd. Company Information
  21. 7.4.2 Zenith Epigenetics Ltd. Business Overview
  22. 7.4.3 Zenith Epigenetics Ltd. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Zenith Epigenetics Ltd. Metastatic Prostate Product Portfolio
  24. 7.4.5 Zenith Epigenetics Ltd. Recent Developments
  25. 7.5 VasGene Therapeutics, Inc.
  26. 7.5.1 VasGene Therapeutics, Inc. Company Information
  27. 7.5.2 VasGene Therapeutics, Inc. Business Overview
  28. 7.5.3 VasGene Therapeutics, Inc. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  29. 7.5.4 VasGene Therapeutics, Inc. Metastatic Prostate Product Portfolio
  30. 7.5.5 VasGene Therapeutics, Inc. Recent Developments
  31. 7.6 Telix Pharmaceuticals
  32. 7.6.1 Telix Pharmaceuticals Company Information
  33. 7.6.2 Telix Pharmaceuticals Business Overview
  34. 7.6.3 Telix Pharmaceuticals Metastatic Prostate Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Telix Pharmaceuticals Metastatic Prostate Product Portfolio
  36. 7.6.5 Telix Pharmaceuticals Recent Developments
  37. 7.7 SeleXel
  38. 7.7.1 SeleXel Company Information
  39. 7.7.2 SeleXel Business Overview
  40. 7.7.3 SeleXel Metastatic Prostate Revenue and Gross Margin (2021-2026)
  41. 7.7.4 SeleXel Metastatic Prostate Product Portfolio
  42. 7.7.5 SeleXel Recent Developments
  43. 7.8 Myovant Biosciences
  44. 7.8.1 Myovant Biosciences Company Information
  45. 7.8.2 Myovant Biosciences Business Overview
  46. 7.8.3 Myovant Biosciences Metastatic Prostate Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Myovant Biosciences Metastatic Prostate Product Portfolio
  48. 7.8.5 Myovant Biosciences Recent Developments
  49. 7.9 Immunomedics(Gilead Sciences, Inc.)
  50. 7.9.1 Immunomedics(Gilead Sciences, Inc.) Company Information
  51. 7.9.2 Immunomedics(Gilead Sciences, Inc.) Business Overview
  52. 7.9.3 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Immunomedics(Gilead Sciences, Inc.) Metastatic Prostate Product Portfolio
  54. 7.9.5 Immunomedics(Gilead Sciences, Inc.) Recent Developments
  55. 7.10 eFFECTOR Therapeutics
  56. 7.10.1 eFFECTOR Therapeutics Company Information
  57. 7.10.2 eFFECTOR Therapeutics Business Overview
  58. 7.10.3 eFFECTOR Therapeutics Metastatic Prostate Revenue and Gross Margin (2021-2026)
  59. 7.10.4 eFFECTOR Therapeutics Metastatic Prostate Product Portfolio
  60. 7.10.5 eFFECTOR Therapeutics Recent Developments
  61. 7.11 Arvinas Inc.
  62. 7.11.1 Arvinas Inc. Company Information
  63. 7.11.2 Arvinas Inc. Business Overview
  64. 7.11.3 Arvinas Inc. Metastatic Prostate Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Arvinas Inc. Metastatic Prostate Product Portfolio
  66. 7.11.5 Arvinas Inc. Recent Developments
  67. 7.12 AB Science
  68. 7.12.1 AB Science Company Information
  69. 7.12.2 AB Science Business Overview
  70. 7.12.3 AB Science Metastatic Prostate Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AB Science Metastatic Prostate Product Portfolio
  72. 7.12.5 AB Science Recent Developments
8 North America
  1. 8.1 North America Metastatic Prostate Revenue (2021-2032)
  2. 8.2 North America Metastatic Prostate Revenue by Type (2021-2032)
  3. 8.2.1 North America Metastatic Prostate Revenue by Type (2021-2026)
  4. 8.2.2 North America Metastatic Prostate Revenue by Type (2027-2032)
  5. 8.3 North America Metastatic Prostate Revenue Share by Type (2021-2032)
  6. 8.4 North America Metastatic Prostate Revenue by Application (2021-2032)
  7. 8.4.1 North America Metastatic Prostate Revenue by Application (2021-2026)
  8. 8.4.2 North America Metastatic Prostate Revenue by Application (2027-2032)
  9. 8.5 North America Metastatic Prostate Revenue Share by Application (2021-2032)
  10. 8.6 North America Metastatic Prostate Revenue by Country
  11. 8.6.1 North America Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Metastatic Prostate Revenue by Country (2021-2026)
  13. 8.6.3 North America Metastatic Prostate Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Metastatic Prostate Revenue (2021-2032)
  2. 9.2 Europe Metastatic Prostate Revenue by Type (2021-2032)
  3. 9.2.1 Europe Metastatic Prostate Revenue by Type (2021-2026)
  4. 9.2.2 Europe Metastatic Prostate Revenue by Type (2027-2032)
  5. 9.3 Europe Metastatic Prostate Revenue Share by Type (2021-2032)
  6. 9.4 Europe Metastatic Prostate Revenue by Application (2021-2032)
  7. 9.4.1 Europe Metastatic Prostate Revenue by Application (2021-2026)
  8. 9.4.2 Europe Metastatic Prostate Revenue by Application (2027-2032)
  9. 9.5 Europe Metastatic Prostate Revenue Share by Application (2021-2032)
  10. 9.6 Europe Metastatic Prostate Revenue by Country
  11. 9.6.1 Europe Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Metastatic Prostate Revenue by Country (2021-2026)
  13. 9.6.3 Europe Metastatic Prostate Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Metastatic Prostate Revenue (2021-2032)
  2. 10.2 China Metastatic Prostate Revenue by Type (2021-2032)
  3. 10.2.1 China Metastatic Prostate Revenue by Type (2021-2026)
  4. 10.2.2 China Metastatic Prostate Revenue by Type (2027-2032)
  5. 10.3 China Metastatic Prostate Revenue Share by Type (2021-2032)
  6. 10.4 China Metastatic Prostate Revenue by Application (2021-2032)
  7. 10.4.1 China Metastatic Prostate Revenue by Application (2021-2026)
  8. 10.4.2 China Metastatic Prostate Revenue by Application (2027-2032)
  9. 10.5 China Metastatic Prostate Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metastatic Prostate Revenue (2021-2032)
  2. 11.2 Asia Metastatic Prostate Revenue by Type (2021-2032)
  3. 11.2.1 Asia Metastatic Prostate Revenue by Type (2021-2026)
  4. 11.2.2 Asia Metastatic Prostate Revenue by Type (2027-2032)
  5. 11.3 Asia Metastatic Prostate Revenue Share by Type (2021-2032)
  6. 11.4 Asia Metastatic Prostate Revenue by Application (2021-2032)
  7. 11.4.1 Asia Metastatic Prostate Revenue by Application (2021-2026)
  8. 11.4.2 Asia Metastatic Prostate Revenue by Application (2027-2032)
  9. 11.5 Asia Metastatic Prostate Revenue Share by Application (2021-2032)
  10. 11.6 Asia Metastatic Prostate Revenue by Country
  11. 11.6.1 Asia Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Metastatic Prostate Revenue by Country (2021-2026)
  13. 11.6.3 Asia Metastatic Prostate Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metastatic Prostate Revenue (2021-2032)
  2. 12.2 SAMEA Metastatic Prostate Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Metastatic Prostate Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Metastatic Prostate Revenue by Type (2027-2032)
  5. 12.3 SAMEA Metastatic Prostate Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Metastatic Prostate Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Metastatic Prostate Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Metastatic Prostate Revenue by Application (2027-2032)
  9. 12.5 SAMEA Metastatic Prostate Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Metastatic Prostate Revenue by Country
  11. 12.6.1 SAMEA Metastatic Prostate Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Metastatic Prostate Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Metastatic Prostate Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst